21
Participants
Start Date
August 4, 2014
Primary Completion Date
July 5, 2017
Study Completion Date
September 22, 2017
Dalantercept plus sorafenib
Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily.
The University of Chicago Medical Center, Chicago
University of Kansas Medical Center (KUMC), Westwood
Beth Israel Deaconess Medical Center (BIDMC), Boston
Hackensack University Medical Center, Hackensack
Memorial Sloan-Kettering Cancer Center, New York
University of Rochester, Rochester
University of Cincinnati Cancer Institute, Cincinnati
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
INDUSTRY